Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Charter Communications Inc (CHTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Charter Communications Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.93 (market cap $29.60B), while Charter Communications Inc trades at $150.26 (market cap $18.81B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Charter Communications Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CHTR | |
|---|---|---|
Market Cap | $29.60B | $18.81B |
Sector | Health | Media |
52-Week High | $491.22 | $282.74 |
52-Week Low | $205.48 | $123.31 |
Enterprise Value | $27.56B | $115.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Charter Communications (CHTR) trades at $149.86, down 2.24% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits low valuation multiples with a P/E of 4.1 and P/S of 0.37, while profitability remains solid with a 9.05% net income margin. Recent Q2 2026 earnings beat estimates, though revenue declined year-over-year, and the company has been active in debt management, pricing $4.75 billion in senior secured notes in early August 2026.
The outlook is mixed; the low valuation presents a potential opportunity, but risks include persistent broadband subscriber losses, high debt levels, and competitive pressures. Analyst consensus leans slightly bullish with a $166.18 price target, though sentiment is cautious due to operational headwinds. The stock's trajectory hinges on reversing subscriber trends and managing leverage effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
